ArticleClinical and translational medicine2025

RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma.

Sara Egea-Rodriguez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.